1. High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
- Author
-
José A. Fernández-Gutiérrez, Oscar A. Reyes-Cisneros, Mark R. Litzow, Lorena Bojalil-Álvarez, Elizabeth García-Villaseñor, Eliezer Tomas Gómez-Gomez, Iván Murrieta-Álvarez, David Gomez-Almaguer, Cesar H. Gutierrez-Aguirre, Amado J. Karduss-Urueta, Guillermo J. Ruiz-Delgado, and Guillermo José Ruiz-Argüelles
- Subjects
Transplantation Conditioning ,Lymphoma ,Antineoplastic Combined Chemotherapy Protocols ,Hematopoietic Stem Cell Transplantation ,Humans ,Female ,Hematology ,Melphalan ,Transplantation, Autologous ,Etoposide - Abstract
High-dose melphalan (HD-Mel) has been successfully employed in autografting patients with multiple myeloma. An advantage of this regimen is that the total dose of Mel can be delivered in a single day, being particularly useful when non-frozen hematopoietic stem cells are employed in the autograft.All consecutive patients with R/R lymphomas, both HL and NHL studied and treated at two different centers were prospectively included in a study of ASCT employing a single dose of HD-Mel (200 mg/mTwenty-five R/R HL/NHL patients were prospectively accrued in the study. There were 8 (32%) females, 13 (52%) patients had at least 1 adverse effect: 7 (28%) developed mucositis, 5 (20%) neutropenic fever, and 6 (24%) grade IV nausea. In the HD-Mel group, median overall survival (OS) was not achieved and OS at 36 months was 71%, the transplant-related mortality being 0%. In the control group, median OS was not achieved and the 36-month OS was 76%, results not statistically significant (HD-Mel alone is non-inferior to a BEAM-like regimen as a preparative regimen for autografting patients with R/R HL and NHL. The regimen is adequate to graft persons with non-frozen stem cells.
- Published
- 2022